After leukemic transformation, ischemic cardiovascular disease (iCVD) is the pathology with higher risk in CHIP carriers, with an estimated 2‐fold increased risk of coronary heart disease and a 4‐fold increased risk of myocardial infarction in CHIP carriers compared to non‐carriers, with the strongest associations observed for TET2‐ and JAK2‐mutant cases. This evidence concerns the gene STUB1 and myocardial infarction.